COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,386 Articles (22,816 medRxiv, 8,570 bioRxiv)

Most recent first Previous |  Page 773: Articles 7721-7730  | Next

Anti-COVID-19 Activity of FDA Approved Drugs through RNA G-quadruplex Binding
Roy, S. S., Sharma, S., Rizvi, Z. A., Sinha, D., Gupta, D., Rophina, M., Sehgal, P., Sadhu, S., Tripathy, M. R., Samal, S., Maiti, S., Scaria, V., Sivasubbu, S., Awasthi, A., Harshan, K., Jain, S., Chowdhury, S.
10.1101/2022.05.31.493843 — Posted: 2022-06-01
SARS-CoV-2 Variant Spike and accessory gene mutations alter pathogenesis
McGrath, M., Xue, Y., Dillen, C., Oldfield, L., Assad-Garcia, N., Zaveri, J., Singh, N., Baracco, L., Taylor, L., Vashee, S., Frieman, M.
10.1101/2022.05.31.494211 — Posted: 2022-06-01
Plasmacytoid dendritic cells regulate megakaryocyte and platelet homeostasis
Gaertner, F., Ishikawa-Ankerhold, H., Stutte, S., Fu, W., Guo, C., Weitz, J., Dueck, A., Zhang, Z., van den Heuvel, D., Fumagalli, V., Lorenz, M., von Baumgarten, L., Stark, K., Straub, T., von Stillfried, S., Boor, P., Colonna, M., Schulz, C., Brocker, T., Walzog, B., Scheiermann, C., Engelhardt, S., Aird, W. C., Petzold, T., Sixt, M., Rudelius, M., Nerlov, C., Iannacone, M., Oostendorp, R. A. J., Massberg, S.
10.1101/2022.05.31.494147 — Posted: 2022-06-01
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Liu, X., Li, Y., Wang, Z., Cao, S., Huang, W., Yuan, L., Huang, Y.-J., Zheng, Y., Chen, J., Ying, B., Xiang, Z., Shi, J., Zhao, J., Huang, Z., Qin, C.-F.
10.1101/2022.05.30.22275753 — Posted: 2022-05-31
Lineage BA.2 dominated the Omicron SARS-CoV-2 epidemic wave in the Philippines
Li, Y.-T., Polotan, F. G. M., Sotelo, G. I. S., Alpino, A. P. A., Dolor, A. Y. M., Tujan, M. A. A., Gomez, M. R. R., Onza, O. J. T., Chang, A. K. T., Bautista, C. T., Carandang, J. C., Lim, D. R., Dancel, L. L. M., Lumandas, M. U., Dizon, T. J. R., Hampson, K., Daldry, S., Hughes, J., Brunker, K.
10.1101/2022.05.30.22275783 — Posted: 2022-05-31
Immunity response against mild-to-moderate breakthrough COVID-19
Mongkolsucharitkul, P., Surawit, A., Sookrung, N., Tungtrongchitr, A., Phisalprapa, P., Sayabovorn, N., Srivanichakorn, W., Washirasaksiri, C., Auesomwang, C., Sitasuwan, T., Chaisathaphol, T., Tinmanee, R., Chayakulkeeree, M., Phoompoung, P., Tangjittipokin, W., Senawong, S., Sanpawitayakul, G., Muangman, S., Mayurasakorn, K.
10.1101/2022.05.30.22275050 — Posted: 2022-05-31
The cost of the COVID-19 pandemic vs the cost-effectiveness of mitigation strategies in the EU/UK/EEA and OECD countries: a systematic review
Vardavas, C., Zisis, K., Nikitara, K., Lagou, I., Aslanoglou, K., Athanasakis, K., Phalkey, R., Leonardi-Bee, J., Fernandez, E., Condell, O., Lamb, F., Sandmann, F., Pharris, A., Deogan, C., Suk, J. E.
10.1101/2022.05.31.22275813 — Posted: 2022-05-31
SARS-CoV-2 impacts the transcriptome and epigenome at the maternal-fetal interface in pregnancy
Gao, L., Mathur, V., Tam, S. K. M., Zhou, X., Cheung, M. F., Chan, L. Y., Estrada-Gutierrez, G., Leung, B. W., Moungmaithong, S., Wang, C. C., Poon, L., Leung, D. C. Y.
10.1101/2022.05.31.494153 — Posted: 2022-05-31
Comprehensive characterization of the transcriptional response to COVID-19 in multiple organs reveals shared signatures across tissues
The COVID Tissue Atlas Consortium, , Granados, A. A., Bucher, S., Agrawal, A., Song, H., Chen, A. T., Peng, T., Neff, N., Pisco, A. O., Huang, F., Wang, B.
10.1101/2022.05.31.493925 — Posted: 2022-05-31
The salivary and nasopharyngeal microbiomes are associated with SARS-CoV-2 infection and disease severity
Kim, J. G., Zhang, A., Rauseo, A. M., Goss, C. W., Mudd, P. A., O'Halloran, J., Wang, L.
10.1101/2022.05.31.494162 — Posted: 2022-05-31

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).